AUA 2017: State-of-the-Art Lecture: Immunotherapy for Bladder Cancer – UroToday
|
AUA 2017: State-of-the-Art Lecture: Immunotherapy for Bladder Cancer
UroToday There is no doubt that more of these drugs will be shown to have favorable 1st-line activity, and we should expect to see the indication for immunotherapy continue to creep forward in the treatment algorithm for high-risk and/or metastatic bladder cancer. |
